QBW251 is a type of CFTR Modulator called a “potentiator”. Similar to the drug ivacaftor, this drug would help to facilitate the opening of the chloride channel on the cell surface. This compound is administered through an oral pill.
Phase 2a trials were completed in individuals with residual function mutations.
This program is sponsored by Novartis and is being conducted within CFFT's Therapeutics Development Network.
Contact us about QBW251 >